Form 4: Ligand Pharma Director Exercises Stock Options

Ligand Pharmaceuticals director Jason Aryeh exercised non-qualified stock options to acquire 2,034 shares of common stock at $69.51 per share.

Summary

• Jason Aryeh, a Director of Ligand Pharmaceuticals Inc. (LGND), reported a transaction involving the company's common stock.
• On December 8, 2025, Mr. Aryeh acquired 2,034 shares of common stock by exercising non-qualified stock options at a price of $69.51 per share.
• This transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled.
• Following this transaction, Mr. Aryeh directly beneficially owns 71,323 shares of common stock.
• Additionally, he indirectly beneficially owns 51,594 shares through funds managed by JALAA Equities, LP and JLV Investments, LP and affiliates, and 5,025 shares by Trust, totaling 127,942 shares.
• The exercised option was previously reported as a grant of 2,329 shares, which vested on May 23, 2016, at an original exercise price of $119.3000 per share, but was adjusted due to the OmniAb Inc. separation from the issuer.

Sentiment

Score: 6

Explanation: This is a routine insider transaction, specifically the exercise of stock options under a pre-planned Rule 10b5-1 arrangement. While the exercise itself is a positive for the insider due to the adjusted price, it does not provide new fundamental information about the company's performance or strategic direction, thus maintaining a largely neutral sentiment with a slight positive tilt due to insider activity.

Positives

• The exercise of stock options by a director can be interpreted as a sign of continued confidence in the company's long-term prospects, even if it is a pre-planned event.
• The transaction was executed at an exercise price of $69.51, which is lower than the original grant price of $119.3000, indicating a favorable outcome for the insider due to the option adjustment.

Future Outlook

The transaction is scheduled for a future date (December 8, 2025) and was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged, automatic transaction designed to avoid insider trading concerns. This suggests a planned execution rather than a discretionary decision based on immediate market conditions.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a director exercising stock options. It does not provide information relevant to broader industry trends or competitive analysis. Such filings are standard compliance requirements for publicly traded companies and their insiders.

Related Party Transactions

• Jason Aryeh indirectly beneficially owns 51,594 shares through funds managed by JALAA Equities, LP and JLV Investments, LP and affiliates, where he serves as a General Partner or Partner. This structure is disclosed as part of his beneficial ownership.

Stakeholder Impact

• The exercise of stock options by a director is a routine compliance event with minimal direct impact on shareholders, employees, customers, suppliers, or creditors. It primarily affects the director's personal equity holdings and is a standard part of executive compensation and insider reporting.

Key Dates

Recommendation

This Form 4 reports a routine insider transaction involving the exercise of stock options under a pre-planned Rule 10b5-1 arrangement. Such transactions are generally not indicative of a change in the company's fundamental outlook or a reason to alter an investment thesis. The exercise price is below the original grant price, which is a benefit to the insider, but does not provide new information for a broader investment decision.

Keywords

Ligand Pharmaceuticals, LGND, Form 4, Insider Transaction, Stock Option Exercise, Director, Beneficial Ownership, Jason Aryeh, Rule 10b5-1